"Product Code",Visible,Findable,"On Demand",File,"Image File","Graph Image File","Report Type",Title,"Licence Type",Price,Topic,Sectors,"Hot topics",Geography,"Number Of Pages","Publication Date",Synopsis,"Executive Summary",Scope,"Reasons To Buy","Key Highlights",Keywords,"Companies Mentioned","Table Of Contents","List Of Tables","List Of Figures","Project Value","project Stage",Quote,"Quote Source","Redirect URL",Tags,"Is Company","Current URI","Topic Id",Methodology,"Unique ID"
GDHCDR1188NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's OpRegen</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's OpRegen Drug Details:</strong></p>

<p> OpRegen is under development for the treatment of geographic atrophy, severe dry-form of age-related macular degeneration (AMD). The drug candidate is administered into the sub-retinal space during an intraocular injection. It is a suspension of retinal pigment epithelial (RPE) cells which are embryonic stem cell-derived RPE cells.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's OpRegen Drug Details:</strong></p>

<p> OpRegen is under development for the treatment of geographic atrophy, severe dry-form of age-related macular degeneration (AMD). The drug candidate is administered into the sub-retinal space during an intraocular injection. It is a suspension of retinal pigment epithelial (RPE) cells which are embryonic stem cell-derived RPE cells.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-opregen-npv-innovation-and-trend-analysis,10374,,1188
GDHCDR1188NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's OpRegen</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's OpRegen Drug Details:</strong></p>

<p> OpRegen is under development for the treatment of geographic atrophy, severe dry-form of age-related macular degeneration (AMD). The drug candidate is administered into the sub-retinal space during an intraocular injection. It is a suspension of retinal pigment epithelial (RPE) cells which are embryonic stem cell-derived RPE cells.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's OpRegen Drug Details:</strong></p>

<p> OpRegen is under development for the treatment of geographic atrophy, severe dry-form of age-related macular degeneration (AMD). The drug candidate is administered into the sub-retinal space during an intraocular injection. It is a suspension of retinal pigment epithelial (RPE) cells which are embryonic stem cell-derived RPE cells.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-opregen-npv-innovation-and-trend-analysis,10374,,1188
GDHCDR1188NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's OpRegen</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's OpRegen Drug Details:</strong></p>

<p> OpRegen is under development for the treatment of geographic atrophy, severe dry-form of age-related macular degeneration (AMD). The drug candidate is administered into the sub-retinal space during an intraocular injection. It is a suspension of retinal pigment epithelial (RPE) cells which are embryonic stem cell-derived RPE cells.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's OpRegen Drug Details:</strong></p>

<p> OpRegen is under development for the treatment of geographic atrophy, severe dry-form of age-related macular degeneration (AMD). The drug candidate is administered into the sub-retinal space during an intraocular injection. It is a suspension of retinal pigment epithelial (RPE) cells which are embryonic stem cell-derived RPE cells.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-opregen-npv-innovation-and-trend-analysis,10374,,1188
GDHCDR1189NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's Balovaptan</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Balovaptan Drug Details:</strong></p>

<p>Balovaptan (RG-7314) is under development for the treatment of post-traumatic stress disorder. The drug candidate is administered through intravenous and orally. It is a new molecular entity (NME) targeting vasopressin (V1a) receptor. It was also under development for the treatment of autism spectrum disorder in peadiatrics. It was also under development for the treatment of autism spectrum disorder in adults and acute ischemic stroke at high risk of developing malignant cerebral edema.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Balovaptan Drug Details:</strong></p>

<p>Balovaptan (RG-7314) is under development for the treatment of post-traumatic stress disorder. The drug candidate is administered through intravenous and orally. It is a new molecular entity (NME) targeting vasopressin (V1a) receptor. It was also under development for the treatment of autism spectrum disorder in peadiatrics. It was also under development for the treatment of autism spectrum disorder in adults and acute ischemic stroke at high risk of developing malignant cerebral edema.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-balovaptan-npv-innovation-and-trend-analysis,10374,,1189
GDHCDR1189NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's Balovaptan</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Balovaptan Drug Details:</strong></p>

<p>Balovaptan (RG-7314) is under development for the treatment of post-traumatic stress disorder. The drug candidate is administered through intravenous and orally. It is a new molecular entity (NME) targeting vasopressin (V1a) receptor. It was also under development for the treatment of autism spectrum disorder in peadiatrics. It was also under development for the treatment of autism spectrum disorder in adults and acute ischemic stroke at high risk of developing malignant cerebral edema.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Balovaptan Drug Details:</strong></p>

<p>Balovaptan (RG-7314) is under development for the treatment of post-traumatic stress disorder. The drug candidate is administered through intravenous and orally. It is a new molecular entity (NME) targeting vasopressin (V1a) receptor. It was also under development for the treatment of autism spectrum disorder in peadiatrics. It was also under development for the treatment of autism spectrum disorder in adults and acute ischemic stroke at high risk of developing malignant cerebral edema.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-balovaptan-npv-innovation-and-trend-analysis,10374,,1189
GDHCDR1189NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's Balovaptan</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Balovaptan Drug Details:</strong></p>

<p>Balovaptan (RG-7314) is under development for the treatment of post-traumatic stress disorder. The drug candidate is administered through intravenous and orally. It is a new molecular entity (NME) targeting vasopressin (V1a) receptor. It was also under development for the treatment of autism spectrum disorder in peadiatrics. It was also under development for the treatment of autism spectrum disorder in adults and acute ischemic stroke at high risk of developing malignant cerebral edema.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Balovaptan Drug Details:</strong></p>

<p>Balovaptan (RG-7314) is under development for the treatment of post-traumatic stress disorder. The drug candidate is administered through intravenous and orally. It is a new molecular entity (NME) targeting vasopressin (V1a) receptor. It was also under development for the treatment of autism spectrum disorder in peadiatrics. It was also under development for the treatment of autism spectrum disorder in adults and acute ischemic stroke at high risk of developing malignant cerebral edema.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-balovaptan-npv-innovation-and-trend-analysis,10374,,1189
GDHCDR1190NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's IONIS-FB-LRx</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's IONIS-FB-LRx Drug Details:</strong></p>

<p>IONIS-FB-LRx is under development for the treatment of geographic atrophy associated dry age-related macular disease and complement-mediated diseases including primary immunoglobulin A (IgA) nephropathy. It is a ligand conjugated antisense oligonucleotide (LICA) targeting complement factor b. It is administered through subcutaneous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's IONIS-FB-LRx Drug Details:</strong></p>

<p>IONIS-FB-LRx is under development for the treatment of geographic atrophy associated dry age-related macular disease and complement-mediated diseases including primary immunoglobulin A (IgA) nephropathy. It is a ligand conjugated antisense oligonucleotide (LICA) targeting complement factor b. It is administered through subcutaneous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-ionis-fb-lrx-npv-innovation-and-trend-analysis,10374,,1190
GDHCDR1190NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's IONIS-FB-LRx</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's IONIS-FB-LRx Drug Details:</strong></p>

<p>IONIS-FB-LRx is under development for the treatment of geographic atrophy associated dry age-related macular disease and complement-mediated diseases including primary immunoglobulin A (IgA) nephropathy. It is a ligand conjugated antisense oligonucleotide (LICA) targeting complement factor b. It is administered through subcutaneous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's IONIS-FB-LRx Drug Details:</strong></p>

<p>IONIS-FB-LRx is under development for the treatment of geographic atrophy associated dry age-related macular disease and complement-mediated diseases including primary immunoglobulin A (IgA) nephropathy. It is a ligand conjugated antisense oligonucleotide (LICA) targeting complement factor b. It is administered through subcutaneous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-ionis-fb-lrx-npv-innovation-and-trend-analysis,10374,,1190
GDHCDR1190NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's IONIS-FB-LRx</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's IONIS-FB-LRx Drug Details:</strong></p>

<p>IONIS-FB-LRx is under development for the treatment of geographic atrophy associated dry age-related macular disease and complement-mediated diseases including primary immunoglobulin A (IgA) nephropathy. It is a ligand conjugated antisense oligonucleotide (LICA) targeting complement factor b. It is administered through subcutaneous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's IONIS-FB-LRx Drug Details:</strong></p>

<p>IONIS-FB-LRx is under development for the treatment of geographic atrophy associated dry age-related macular disease and complement-mediated diseases including primary immunoglobulin A (IgA) nephropathy. It is a ligand conjugated antisense oligonucleotide (LICA) targeting complement factor b. It is administered through subcutaneous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-ionis-fb-lrx-npv-innovation-and-trend-analysis,10374,,1190
GDHCDR1191NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Sanofi's Amlitelimab</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Sanofi's Amlitelimab Drug Details:</strong></p>

<p>Amlitelimab (KY-1005) is under development for the treatment of hidradenitis suppurativa, graft-versus-host disease, mild-to-moderate psoriasis, atopic dermatitis, asthma and other immune mediated disease. It is administered through intravenous and subcutaneous routes as an  infusion. The drug candidate is a humanized bi-specific monoclonal antibody which acts by targeting OX40L. It is developed based on Kymouse technology. </p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Sanofi's Amlitelimab Drug Details:</strong></p>

<p>Amlitelimab (KY-1005) is under development for the treatment of hidradenitis suppurativa, graft-versus-host disease, mild-to-moderate psoriasis, atopic dermatitis, asthma and other immune mediated disease. It is administered through intravenous and subcutaneous routes as an  infusion. The drug candidate is a humanized bi-specific monoclonal antibody which acts by targeting OX40L. It is developed based on Kymouse technology. </p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,Sanofi,,,,,,,,,,,sanofis-amlitelimab-npv-innovation-and-trend-analysis,10374,,1191
GDHCDR1191NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Sanofi's Amlitelimab</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Sanofi's Amlitelimab Drug Details:</strong></p>

<p>Amlitelimab (KY-1005) is under development for the treatment of hidradenitis suppurativa, graft-versus-host disease, mild-to-moderate psoriasis, atopic dermatitis, asthma and other immune mediated disease. It is administered through intravenous and subcutaneous routes as an  infusion. The drug candidate is a humanized bi-specific monoclonal antibody which acts by targeting OX40L. It is developed based on Kymouse technology. </p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Sanofi's Amlitelimab Drug Details:</strong></p>

<p>Amlitelimab (KY-1005) is under development for the treatment of hidradenitis suppurativa, graft-versus-host disease, mild-to-moderate psoriasis, atopic dermatitis, asthma and other immune mediated disease. It is administered through intravenous and subcutaneous routes as an  infusion. The drug candidate is a humanized bi-specific monoclonal antibody which acts by targeting OX40L. It is developed based on Kymouse technology. </p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,Sanofi,,,,,,,,,,,sanofis-amlitelimab-npv-innovation-and-trend-analysis,10374,,1191
GDHCDR1191NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Sanofi's Amlitelimab</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Sanofi's Amlitelimab Drug Details:</strong></p>

<p>Amlitelimab (KY-1005) is under development for the treatment of hidradenitis suppurativa, graft-versus-host disease, mild-to-moderate psoriasis, atopic dermatitis, asthma and other immune mediated disease. It is administered through intravenous and subcutaneous routes as an  infusion. The drug candidate is a humanized bi-specific monoclonal antibody which acts by targeting OX40L. It is developed based on Kymouse technology. </p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Sanofi's Amlitelimab Drug Details:</strong></p>

<p>Amlitelimab (KY-1005) is under development for the treatment of hidradenitis suppurativa, graft-versus-host disease, mild-to-moderate psoriasis, atopic dermatitis, asthma and other immune mediated disease. It is administered through intravenous and subcutaneous routes as an  infusion. The drug candidate is a humanized bi-specific monoclonal antibody which acts by targeting OX40L. It is developed based on Kymouse technology. </p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,Sanofi,,,,,,,,,,,sanofis-amlitelimab-npv-innovation-and-trend-analysis,10374,,1191
GDHCDR1192NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Takeda Pharmaceutical Co Ltd's Mezagitamab</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Mezagitamab Drug Details:</strong></p>

<p>Mezagitamab (TAK-079) is under development for the treatment of primary immune thrombocytopenia, myasthenia gravis, primary IgA nephropathy, systemic lupus erythematosus, relapsed/refractory multiple myeloma and newly diagnosed multiple myeloma. The drug candidate is administered intravenously or subcutaneously. It is an anti-CD38 human IgG1 monoclonal antibody. It was under development for the treatment of rheumatoid arthritis.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Mezagitamab Drug Details:</strong></p>

<p>Mezagitamab (TAK-079) is under development for the treatment of primary immune thrombocytopenia, myasthenia gravis, primary IgA nephropathy, systemic lupus erythematosus, relapsed/refractory multiple myeloma and newly diagnosed multiple myeloma. The drug candidate is administered intravenously or subcutaneously. It is an anti-CD38 human IgG1 monoclonal antibody. It was under development for the treatment of rheumatoid arthritis.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Takeda Pharmaceutical Co Ltd",,,,,,,,,,,takeda-pharmaceutical-co-ltds-mezagitamab-npv-innovation-and-trend-analysis,10374,,1192
GDHCDR1192NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Takeda Pharmaceutical Co Ltd's Mezagitamab</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Mezagitamab Drug Details:</strong></p>

<p>Mezagitamab (TAK-079) is under development for the treatment of primary immune thrombocytopenia, myasthenia gravis, primary IgA nephropathy, systemic lupus erythematosus, relapsed/refractory multiple myeloma and newly diagnosed multiple myeloma. The drug candidate is administered intravenously or subcutaneously. It is an anti-CD38 human IgG1 monoclonal antibody. It was under development for the treatment of rheumatoid arthritis.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Mezagitamab Drug Details:</strong></p>

<p>Mezagitamab (TAK-079) is under development for the treatment of primary immune thrombocytopenia, myasthenia gravis, primary IgA nephropathy, systemic lupus erythematosus, relapsed/refractory multiple myeloma and newly diagnosed multiple myeloma. The drug candidate is administered intravenously or subcutaneously. It is an anti-CD38 human IgG1 monoclonal antibody. It was under development for the treatment of rheumatoid arthritis.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Takeda Pharmaceutical Co Ltd",,,,,,,,,,,takeda-pharmaceutical-co-ltds-mezagitamab-npv-innovation-and-trend-analysis,10374,,1192
GDHCDR1192NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Takeda Pharmaceutical Co Ltd's Mezagitamab</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Mezagitamab Drug Details:</strong></p>

<p>Mezagitamab (TAK-079) is under development for the treatment of primary immune thrombocytopenia, myasthenia gravis, primary IgA nephropathy, systemic lupus erythematosus, relapsed/refractory multiple myeloma and newly diagnosed multiple myeloma. The drug candidate is administered intravenously or subcutaneously. It is an anti-CD38 human IgG1 monoclonal antibody. It was under development for the treatment of rheumatoid arthritis.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Mezagitamab Drug Details:</strong></p>

<p>Mezagitamab (TAK-079) is under development for the treatment of primary immune thrombocytopenia, myasthenia gravis, primary IgA nephropathy, systemic lupus erythematosus, relapsed/refractory multiple myeloma and newly diagnosed multiple myeloma. The drug candidate is administered intravenously or subcutaneously. It is an anti-CD38 human IgG1 monoclonal antibody. It was under development for the treatment of rheumatoid arthritis.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Takeda Pharmaceutical Co Ltd",,,,,,,,,,,takeda-pharmaceutical-co-ltds-mezagitamab-npv-innovation-and-trend-analysis,10374,,1192
GDHCDR1193NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Acelyrin Inc's Izokibep</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Acelyrin Inc's Izokibep Drug Details:</strong></p>

<p>Izokibep (ABY-035) is under development for the treatment of posterior uveitis, panuveitis, non-infectious uveitis, intermediate uveitis, patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis with inflammatory musculoskeletal disease, hidradenitis suppurativa. It is administered through subcutaneous route. ABY-035 is a IL-17A blocking molecule. It is developed based on affibody technology. Affibody molecules are antibody mimetics with superior characteristics surpassing monoclonal antibodies and antibody fragments. It was also under development for Takayasu arteritis.It was also under development for the treatment of ankylosing spondylitis(AS).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Acelyrin Inc's Izokibep Drug Details:</strong></p>

<p>Izokibep (ABY-035) is under development for the treatment of posterior uveitis, panuveitis, non-infectious uveitis, intermediate uveitis, patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis with inflammatory musculoskeletal disease, hidradenitis suppurativa. It is administered through subcutaneous route. ABY-035 is a IL-17A blocking molecule. It is developed based on affibody technology. Affibody molecules are antibody mimetics with superior characteristics surpassing monoclonal antibodies and antibody fragments. It was also under development for Takayasu arteritis.It was also under development for the treatment of ankylosing spondylitis(AS).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Acelyrin Inc",,,,,,,,,,,acelyrin-incs-izokibep-npv-innovation-and-trend-analysis,10374,,1193
GDHCDR1193NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Acelyrin Inc's Izokibep</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Acelyrin Inc's Izokibep Drug Details:</strong></p>

<p>Izokibep (ABY-035) is under development for the treatment of posterior uveitis, panuveitis, non-infectious uveitis, intermediate uveitis, patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis with inflammatory musculoskeletal disease, hidradenitis suppurativa. It is administered through subcutaneous route. ABY-035 is a IL-17A blocking molecule. It is developed based on affibody technology. Affibody molecules are antibody mimetics with superior characteristics surpassing monoclonal antibodies and antibody fragments. It was also under development for Takayasu arteritis.It was also under development for the treatment of ankylosing spondylitis(AS).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Acelyrin Inc's Izokibep Drug Details:</strong></p>

<p>Izokibep (ABY-035) is under development for the treatment of posterior uveitis, panuveitis, non-infectious uveitis, intermediate uveitis, patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis with inflammatory musculoskeletal disease, hidradenitis suppurativa. It is administered through subcutaneous route. ABY-035 is a IL-17A blocking molecule. It is developed based on affibody technology. Affibody molecules are antibody mimetics with superior characteristics surpassing monoclonal antibodies and antibody fragments. It was also under development for Takayasu arteritis.It was also under development for the treatment of ankylosing spondylitis(AS).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Acelyrin Inc",,,,,,,,,,,acelyrin-incs-izokibep-npv-innovation-and-trend-analysis,10374,,1193
GDHCDR1193NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Acelyrin Inc's Izokibep</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Acelyrin Inc's Izokibep Drug Details:</strong></p>

<p>Izokibep (ABY-035) is under development for the treatment of posterior uveitis, panuveitis, non-infectious uveitis, intermediate uveitis, patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis with inflammatory musculoskeletal disease, hidradenitis suppurativa. It is administered through subcutaneous route. ABY-035 is a IL-17A blocking molecule. It is developed based on affibody technology. Affibody molecules are antibody mimetics with superior characteristics surpassing monoclonal antibodies and antibody fragments. It was also under development for Takayasu arteritis.It was also under development for the treatment of ankylosing spondylitis(AS).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Acelyrin Inc's Izokibep Drug Details:</strong></p>

<p>Izokibep (ABY-035) is under development for the treatment of posterior uveitis, panuveitis, non-infectious uveitis, intermediate uveitis, patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis with inflammatory musculoskeletal disease, hidradenitis suppurativa. It is administered through subcutaneous route. ABY-035 is a IL-17A blocking molecule. It is developed based on affibody technology. Affibody molecules are antibody mimetics with superior characteristics surpassing monoclonal antibodies and antibody fragments. It was also under development for Takayasu arteritis.It was also under development for the treatment of ankylosing spondylitis(AS).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Acelyrin Inc",,,,,,,,,,,acelyrin-incs-izokibep-npv-innovation-and-trend-analysis,10374,,1193
GDHCDR1194NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Novo Nordisk AS's NNC-6019</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's NNC-6019 Drug Details:</strong></p>

<p>PRX-004 is under development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) and familial amyloid polyneuropathy. It is administered through intravenous route. The therapeutic candidate is a monoclonal antibody which acts by targeting misfolded transthyretin (TTR) protein.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's NNC-6019 Drug Details:</strong></p>

<p>PRX-004 is under development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) and familial amyloid polyneuropathy. It is administered through intravenous route. The therapeutic candidate is a monoclonal antibody which acts by targeting misfolded transthyretin (TTR) protein.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Novo Nordisk AS",,,,,,,,,,,novo-nordisk-ass-nnc-6019-npv-innovation-and-trend-analysis,10374,,1194
GDHCDR1194NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Novo Nordisk AS's NNC-6019</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's NNC-6019 Drug Details:</strong></p>

<p>PRX-004 is under development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) and familial amyloid polyneuropathy. It is administered through intravenous route. The therapeutic candidate is a monoclonal antibody which acts by targeting misfolded transthyretin (TTR) protein.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's NNC-6019 Drug Details:</strong></p>

<p>PRX-004 is under development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) and familial amyloid polyneuropathy. It is administered through intravenous route. The therapeutic candidate is a monoclonal antibody which acts by targeting misfolded transthyretin (TTR) protein.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Novo Nordisk AS",,,,,,,,,,,novo-nordisk-ass-nnc-6019-npv-innovation-and-trend-analysis,10374,,1194
GDHCDR1194NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Novo Nordisk AS's NNC-6019</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's NNC-6019 Drug Details:</strong></p>

<p>PRX-004 is under development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) and familial amyloid polyneuropathy. It is administered through intravenous route. The therapeutic candidate is a monoclonal antibody which acts by targeting misfolded transthyretin (TTR) protein.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's NNC-6019 Drug Details:</strong></p>

<p>PRX-004 is under development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) and familial amyloid polyneuropathy. It is administered through intravenous route. The therapeutic candidate is a monoclonal antibody which acts by targeting misfolded transthyretin (TTR) protein.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Novo Nordisk AS",,,,,,,,,,,novo-nordisk-ass-nnc-6019-npv-innovation-and-trend-analysis,10374,,1194
GDHCDR1195NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Takeda Pharmaceutical Co Ltd's Modakafusp alfa</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Modakafusp alfa Drug Details:</strong></p>

<p>TAK-573 is under development for the treatment of relapsed/refractory multiple myeloma, metastatic solid tumors including metastatic cutaneous melanoma. It is administered through intravenous route. It consists of CD38-targeted IgG4 fused with attenuated interferon (IFN) alpha for tumor-specificity. The therapeutic candidate is a monoclonal antibody fusion protein and it acts by targeting cells expressing CD38. The drug candidate was also under development for the treatment of metastatic castrate-resistant prostate cancer, non-small cell lung cancer, head and neck cancer, pancreatic ductal adenocarcinoma, triple negative breast cancer and microsatellite stable colon cancer.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Modakafusp alfa Drug Details:</strong></p>

<p>TAK-573 is under development for the treatment of relapsed/refractory multiple myeloma, metastatic solid tumors including metastatic cutaneous melanoma. It is administered through intravenous route. It consists of CD38-targeted IgG4 fused with attenuated interferon (IFN) alpha for tumor-specificity. The therapeutic candidate is a monoclonal antibody fusion protein and it acts by targeting cells expressing CD38. The drug candidate was also under development for the treatment of metastatic castrate-resistant prostate cancer, non-small cell lung cancer, head and neck cancer, pancreatic ductal adenocarcinoma, triple negative breast cancer and microsatellite stable colon cancer.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Takeda Pharmaceutical Co Ltd",,,,,,,,,,,takeda-pharmaceutical-co-ltds-modakafusp-alfa-npv-innovation-and-trend-analysis,10374,,1195
GDHCDR1195NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Takeda Pharmaceutical Co Ltd's Modakafusp alfa</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Modakafusp alfa Drug Details:</strong></p>

<p>TAK-573 is under development for the treatment of relapsed/refractory multiple myeloma, metastatic solid tumors including metastatic cutaneous melanoma. It is administered through intravenous route. It consists of CD38-targeted IgG4 fused with attenuated interferon (IFN) alpha for tumor-specificity. The therapeutic candidate is a monoclonal antibody fusion protein and it acts by targeting cells expressing CD38. The drug candidate was also under development for the treatment of metastatic castrate-resistant prostate cancer, non-small cell lung cancer, head and neck cancer, pancreatic ductal adenocarcinoma, triple negative breast cancer and microsatellite stable colon cancer.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Modakafusp alfa Drug Details:</strong></p>

<p>TAK-573 is under development for the treatment of relapsed/refractory multiple myeloma, metastatic solid tumors including metastatic cutaneous melanoma. It is administered through intravenous route. It consists of CD38-targeted IgG4 fused with attenuated interferon (IFN) alpha for tumor-specificity. The therapeutic candidate is a monoclonal antibody fusion protein and it acts by targeting cells expressing CD38. The drug candidate was also under development for the treatment of metastatic castrate-resistant prostate cancer, non-small cell lung cancer, head and neck cancer, pancreatic ductal adenocarcinoma, triple negative breast cancer and microsatellite stable colon cancer.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Takeda Pharmaceutical Co Ltd",,,,,,,,,,,takeda-pharmaceutical-co-ltds-modakafusp-alfa-npv-innovation-and-trend-analysis,10374,,1195
GDHCDR1195NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Takeda Pharmaceutical Co Ltd's Modakafusp alfa</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Modakafusp alfa Drug Details:</strong></p>

<p>TAK-573 is under development for the treatment of relapsed/refractory multiple myeloma, metastatic solid tumors including metastatic cutaneous melanoma. It is administered through intravenous route. It consists of CD38-targeted IgG4 fused with attenuated interferon (IFN) alpha for tumor-specificity. The therapeutic candidate is a monoclonal antibody fusion protein and it acts by targeting cells expressing CD38. The drug candidate was also under development for the treatment of metastatic castrate-resistant prostate cancer, non-small cell lung cancer, head and neck cancer, pancreatic ductal adenocarcinoma, triple negative breast cancer and microsatellite stable colon cancer.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Modakafusp alfa Drug Details:</strong></p>

<p>TAK-573 is under development for the treatment of relapsed/refractory multiple myeloma, metastatic solid tumors including metastatic cutaneous melanoma. It is administered through intravenous route. It consists of CD38-targeted IgG4 fused with attenuated interferon (IFN) alpha for tumor-specificity. The therapeutic candidate is a monoclonal antibody fusion protein and it acts by targeting cells expressing CD38. The drug candidate was also under development for the treatment of metastatic castrate-resistant prostate cancer, non-small cell lung cancer, head and neck cancer, pancreatic ductal adenocarcinoma, triple negative breast cancer and microsatellite stable colon cancer.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Takeda Pharmaceutical Co Ltd",,,,,,,,,,,takeda-pharmaceutical-co-ltds-modakafusp-alfa-npv-innovation-and-trend-analysis,10374,,1195
GDHCDR1196NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's Cevostamab</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Cevostamab Drug Details:</strong></p>

<p>Cevostamab (RO-7187797) is under development for the treatment of multiple myeloma, relapsed or refractory multiple myeloma. The therapeutic candidate is a bi-specific monoclonal antibody, administered by intravenous and subcutaneous route. It is a new molecular entity. It is a anti-FCRH5/CD3 BiTE antibody.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Cevostamab Drug Details:</strong></p>

<p>Cevostamab (RO-7187797) is under development for the treatment of multiple myeloma, relapsed or refractory multiple myeloma. The therapeutic candidate is a bi-specific monoclonal antibody, administered by intravenous and subcutaneous route. It is a new molecular entity. It is a anti-FCRH5/CD3 BiTE antibody.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-cevostamab-npv-innovation-and-trend-analysis,10374,,1196
GDHCDR1196NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's Cevostamab</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Cevostamab Drug Details:</strong></p>

<p>Cevostamab (RO-7187797) is under development for the treatment of multiple myeloma, relapsed or refractory multiple myeloma. The therapeutic candidate is a bi-specific monoclonal antibody, administered by intravenous and subcutaneous route. It is a new molecular entity. It is a anti-FCRH5/CD3 BiTE antibody.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Cevostamab Drug Details:</strong></p>

<p>Cevostamab (RO-7187797) is under development for the treatment of multiple myeloma, relapsed or refractory multiple myeloma. The therapeutic candidate is a bi-specific monoclonal antibody, administered by intravenous and subcutaneous route. It is a new molecular entity. It is a anti-FCRH5/CD3 BiTE antibody.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-cevostamab-npv-innovation-and-trend-analysis,10374,,1196
GDHCDR1196NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's Cevostamab</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Cevostamab Drug Details:</strong></p>

<p>Cevostamab (RO-7187797) is under development for the treatment of multiple myeloma, relapsed or refractory multiple myeloma. The therapeutic candidate is a bi-specific monoclonal antibody, administered by intravenous and subcutaneous route. It is a new molecular entity. It is a anti-FCRH5/CD3 BiTE antibody.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Cevostamab Drug Details:</strong></p>

<p>Cevostamab (RO-7187797) is under development for the treatment of multiple myeloma, relapsed or refractory multiple myeloma. The therapeutic candidate is a bi-specific monoclonal antibody, administered by intravenous and subcutaneous route. It is a new molecular entity. It is a anti-FCRH5/CD3 BiTE antibody.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-cevostamab-npv-innovation-and-trend-analysis,10374,,1196
GDHCDR1197NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's Bepranemab</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Bepranemab Drug Details:</strong></p>

<p>Bepranemab is under development for the treatment of progressive supranuclear palsy, prodromal/mild cognitive impairment due to Alzheimer's disease (AD) or mild Alzheimer's disease and tauopathies. The therapeutic candidate is a recombinant humanized IgG4P administered  intravenously as a solution for infusion. It acts by targeting tau protein.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Bepranemab Drug Details:</strong></p>

<p>Bepranemab is under development for the treatment of progressive supranuclear palsy, prodromal/mild cognitive impairment due to Alzheimer's disease (AD) or mild Alzheimer's disease and tauopathies. The therapeutic candidate is a recombinant humanized IgG4P administered  intravenously as a solution for infusion. It acts by targeting tau protein.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-bepranemab-npv-innovation-and-trend-analysis,10374,,1197
GDHCDR1197NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's Bepranemab</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Bepranemab Drug Details:</strong></p>

<p>Bepranemab is under development for the treatment of progressive supranuclear palsy, prodromal/mild cognitive impairment due to Alzheimer's disease (AD) or mild Alzheimer's disease and tauopathies. The therapeutic candidate is a recombinant humanized IgG4P administered  intravenously as a solution for infusion. It acts by targeting tau protein.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Bepranemab Drug Details:</strong></p>

<p>Bepranemab is under development for the treatment of progressive supranuclear palsy, prodromal/mild cognitive impairment due to Alzheimer's disease (AD) or mild Alzheimer's disease and tauopathies. The therapeutic candidate is a recombinant humanized IgG4P administered  intravenously as a solution for infusion. It acts by targeting tau protein.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-bepranemab-npv-innovation-and-trend-analysis,10374,,1197
GDHCDR1197NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's Bepranemab</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Bepranemab Drug Details:</strong></p>

<p>Bepranemab is under development for the treatment of progressive supranuclear palsy, prodromal/mild cognitive impairment due to Alzheimer's disease (AD) or mild Alzheimer's disease and tauopathies. The therapeutic candidate is a recombinant humanized IgG4P administered  intravenously as a solution for infusion. It acts by targeting tau protein.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's Bepranemab Drug Details:</strong></p>

<p>Bepranemab is under development for the treatment of progressive supranuclear palsy, prodromal/mild cognitive impairment due to Alzheimer's disease (AD) or mild Alzheimer's disease and tauopathies. The therapeutic candidate is a recombinant humanized IgG4P administered  intravenously as a solution for infusion. It acts by targeting tau protein.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-bepranemab-npv-innovation-and-trend-analysis,10374,,1197
GDHCDR1198NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Daiichi Sankyo Co Ltd's Raludotatug Deruxtecan</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Daiichi Sankyo Co Ltd's Raludotatug Deruxtecan Drug Details:</strong></p>

<p>Raludotatug deruxtecan (DS-6000) is under development for the treatment of ovarian and renal cell carcinoma. It is a monoclonal antibody drug conjugate (ADC) comprises of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a tetrapeptide-based cleavable linker It acts by targeting tumor cells expressing cadherin 6 (CDH6) and acts as topoisomerase I inhibitor. It is administered through intravenous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Daiichi Sankyo Co Ltd's Raludotatug Deruxtecan Drug Details:</strong></p>

<p>Raludotatug deruxtecan (DS-6000) is under development for the treatment of ovarian and renal cell carcinoma. It is a monoclonal antibody drug conjugate (ADC) comprises of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a tetrapeptide-based cleavable linker It acts by targeting tumor cells expressing cadherin 6 (CDH6) and acts as topoisomerase I inhibitor. It is administered through intravenous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Daiichi Sankyo Co Ltd",,,,,,,,,,,daiichi-sankyo-co-ltds-raludotatug-deruxtecan-npv-innovation-and-trend-analysis,10374,,1198
GDHCDR1198NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Daiichi Sankyo Co Ltd's Raludotatug Deruxtecan</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Daiichi Sankyo Co Ltd's Raludotatug Deruxtecan Drug Details:</strong></p>

<p>Raludotatug deruxtecan (DS-6000) is under development for the treatment of ovarian and renal cell carcinoma. It is a monoclonal antibody drug conjugate (ADC) comprises of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a tetrapeptide-based cleavable linker It acts by targeting tumor cells expressing cadherin 6 (CDH6) and acts as topoisomerase I inhibitor. It is administered through intravenous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Daiichi Sankyo Co Ltd's Raludotatug Deruxtecan Drug Details:</strong></p>

<p>Raludotatug deruxtecan (DS-6000) is under development for the treatment of ovarian and renal cell carcinoma. It is a monoclonal antibody drug conjugate (ADC) comprises of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a tetrapeptide-based cleavable linker It acts by targeting tumor cells expressing cadherin 6 (CDH6) and acts as topoisomerase I inhibitor. It is administered through intravenous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Daiichi Sankyo Co Ltd",,,,,,,,,,,daiichi-sankyo-co-ltds-raludotatug-deruxtecan-npv-innovation-and-trend-analysis,10374,,1198
GDHCDR1198NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Daiichi Sankyo Co Ltd's Raludotatug Deruxtecan</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Daiichi Sankyo Co Ltd's Raludotatug Deruxtecan Drug Details:</strong></p>

<p>Raludotatug deruxtecan (DS-6000) is under development for the treatment of ovarian and renal cell carcinoma. It is a monoclonal antibody drug conjugate (ADC) comprises of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a tetrapeptide-based cleavable linker It acts by targeting tumor cells expressing cadherin 6 (CDH6) and acts as topoisomerase I inhibitor. It is administered through intravenous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Daiichi Sankyo Co Ltd's Raludotatug Deruxtecan Drug Details:</strong></p>

<p>Raludotatug deruxtecan (DS-6000) is under development for the treatment of ovarian and renal cell carcinoma. It is a monoclonal antibody drug conjugate (ADC) comprises of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a tetrapeptide-based cleavable linker It acts by targeting tumor cells expressing cadherin 6 (CDH6) and acts as topoisomerase I inhibitor. It is administered through intravenous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Daiichi Sankyo Co Ltd",,,,,,,,,,,daiichi-sankyo-co-ltds-raludotatug-deruxtecan-npv-innovation-and-trend-analysis,10374,,1198
GDHCDR1199NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Takeda Pharmaceutical Co Ltd's Subasumstat</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Subasumstat Drug Details:</strong></p>

<p>TAK-981 is under development for the treatment of advanced or metastatic solid tumors including microsatellite stable-colorectal cancer, cervical cancer, non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, small-cell lung cancer, head and neck cancer squamous cell carcinoma, melanoma, head and neck cancer and relapsed or refractory follicular lymphoma, mantle cell lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma, small lymphocytic lymphoma, relapsed or refractory  hematologic malignancy, chronic lymphocytic leukemia, lymphoplasmacytoid lymphoma, marginal zone lymphomas and relapsed or refractory multiple myeloma. The drug candidate is administered through intravenous infusion. It acts by targeting small ubiquitin-related modifier.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Subasumstat Drug Details:</strong></p>

<p>TAK-981 is under development for the treatment of advanced or metastatic solid tumors including microsatellite stable-colorectal cancer, cervical cancer, non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, small-cell lung cancer, head and neck cancer squamous cell carcinoma, melanoma, head and neck cancer and relapsed or refractory follicular lymphoma, mantle cell lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma, small lymphocytic lymphoma, relapsed or refractory  hematologic malignancy, chronic lymphocytic leukemia, lymphoplasmacytoid lymphoma, marginal zone lymphomas and relapsed or refractory multiple myeloma. The drug candidate is administered through intravenous infusion. It acts by targeting small ubiquitin-related modifier.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Takeda Pharmaceutical Co Ltd",,,,,,,,,,,takeda-pharmaceutical-co-ltds-subasumstat-npv-innovation-and-trend-analysis,10374,,1199
GDHCDR1199NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Takeda Pharmaceutical Co Ltd's Subasumstat</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Subasumstat Drug Details:</strong></p>

<p>TAK-981 is under development for the treatment of advanced or metastatic solid tumors including microsatellite stable-colorectal cancer, cervical cancer, non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, small-cell lung cancer, head and neck cancer squamous cell carcinoma, melanoma, head and neck cancer and relapsed or refractory follicular lymphoma, mantle cell lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma, small lymphocytic lymphoma, relapsed or refractory  hematologic malignancy, chronic lymphocytic leukemia, lymphoplasmacytoid lymphoma, marginal zone lymphomas and relapsed or refractory multiple myeloma. The drug candidate is administered through intravenous infusion. It acts by targeting small ubiquitin-related modifier.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Subasumstat Drug Details:</strong></p>

<p>TAK-981 is under development for the treatment of advanced or metastatic solid tumors including microsatellite stable-colorectal cancer, cervical cancer, non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, small-cell lung cancer, head and neck cancer squamous cell carcinoma, melanoma, head and neck cancer and relapsed or refractory follicular lymphoma, mantle cell lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma, small lymphocytic lymphoma, relapsed or refractory  hematologic malignancy, chronic lymphocytic leukemia, lymphoplasmacytoid lymphoma, marginal zone lymphomas and relapsed or refractory multiple myeloma. The drug candidate is administered through intravenous infusion. It acts by targeting small ubiquitin-related modifier.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Takeda Pharmaceutical Co Ltd",,,,,,,,,,,takeda-pharmaceutical-co-ltds-subasumstat-npv-innovation-and-trend-analysis,10374,,1199
GDHCDR1199NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Takeda Pharmaceutical Co Ltd's Subasumstat</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Subasumstat Drug Details:</strong></p>

<p>TAK-981 is under development for the treatment of advanced or metastatic solid tumors including microsatellite stable-colorectal cancer, cervical cancer, non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, small-cell lung cancer, head and neck cancer squamous cell carcinoma, melanoma, head and neck cancer and relapsed or refractory follicular lymphoma, mantle cell lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma, small lymphocytic lymphoma, relapsed or refractory  hematologic malignancy, chronic lymphocytic leukemia, lymphoplasmacytoid lymphoma, marginal zone lymphomas and relapsed or refractory multiple myeloma. The drug candidate is administered through intravenous infusion. It acts by targeting small ubiquitin-related modifier.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's Subasumstat Drug Details:</strong></p>

<p>TAK-981 is under development for the treatment of advanced or metastatic solid tumors including microsatellite stable-colorectal cancer, cervical cancer, non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, small-cell lung cancer, head and neck cancer squamous cell carcinoma, melanoma, head and neck cancer and relapsed or refractory follicular lymphoma, mantle cell lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma, small lymphocytic lymphoma, relapsed or refractory  hematologic malignancy, chronic lymphocytic leukemia, lymphoplasmacytoid lymphoma, marginal zone lymphomas and relapsed or refractory multiple myeloma. The drug candidate is administered through intravenous infusion. It acts by targeting small ubiquitin-related modifier.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Takeda Pharmaceutical Co Ltd",,,,,,,,,,,takeda-pharmaceutical-co-ltds-subasumstat-npv-innovation-and-trend-analysis,10374,,1199
GDHCDR1200NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Repare Therapeutics Inc's Lunresertib</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Repare Therapeutics Inc's Lunresertib Drug Details:</strong></p>

<p> Lunresertib (RP-6306) is under development for the treatment of advanced solid tumors including metastatic colorectal cancer, ovarian, breast, hepatocellular, endometrial cancer, gastroesophageal cancer, fallopian tube cancer, peritoneal cancer, uterine cancer, triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma, non-small cell lung cancer, esophageal cancer, cholangiocarcinoma, breast cancer, head and neck cancer, soft tissue sarcoma, bladder cancer, cervical cancer, gastrointestinal stromal tumor (gist), melanoma, gallbladder cancer, vulvar cancer, sarcomas. It is administered through oral route. It acts by targeting Cyclin E 1 (CCNE1) and PKMYT1.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Repare Therapeutics Inc's Lunresertib Drug Details:</strong></p>

<p> Lunresertib (RP-6306) is under development for the treatment of advanced solid tumors including metastatic colorectal cancer, ovarian, breast, hepatocellular, endometrial cancer, gastroesophageal cancer, fallopian tube cancer, peritoneal cancer, uterine cancer, triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma, non-small cell lung cancer, esophageal cancer, cholangiocarcinoma, breast cancer, head and neck cancer, soft tissue sarcoma, bladder cancer, cervical cancer, gastrointestinal stromal tumor (gist), melanoma, gallbladder cancer, vulvar cancer, sarcomas. It is administered through oral route. It acts by targeting Cyclin E 1 (CCNE1) and PKMYT1.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Repare Therapeutics Inc",,,,,,,,,,,repare-therapeutics-incs-lunresertib-npv-innovation-and-trend-analysis,10374,,1200
GDHCDR1200NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Repare Therapeutics Inc's Lunresertib</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Repare Therapeutics Inc's Lunresertib Drug Details:</strong></p>

<p> Lunresertib (RP-6306) is under development for the treatment of advanced solid tumors including metastatic colorectal cancer, ovarian, breast, hepatocellular, endometrial cancer, gastroesophageal cancer, fallopian tube cancer, peritoneal cancer, uterine cancer, triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma, non-small cell lung cancer, esophageal cancer, cholangiocarcinoma, breast cancer, head and neck cancer, soft tissue sarcoma, bladder cancer, cervical cancer, gastrointestinal stromal tumor (gist), melanoma, gallbladder cancer, vulvar cancer, sarcomas. It is administered through oral route. It acts by targeting Cyclin E 1 (CCNE1) and PKMYT1.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Repare Therapeutics Inc's Lunresertib Drug Details:</strong></p>

<p> Lunresertib (RP-6306) is under development for the treatment of advanced solid tumors including metastatic colorectal cancer, ovarian, breast, hepatocellular, endometrial cancer, gastroesophageal cancer, fallopian tube cancer, peritoneal cancer, uterine cancer, triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma, non-small cell lung cancer, esophageal cancer, cholangiocarcinoma, breast cancer, head and neck cancer, soft tissue sarcoma, bladder cancer, cervical cancer, gastrointestinal stromal tumor (gist), melanoma, gallbladder cancer, vulvar cancer, sarcomas. It is administered through oral route. It acts by targeting Cyclin E 1 (CCNE1) and PKMYT1.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Repare Therapeutics Inc",,,,,,,,,,,repare-therapeutics-incs-lunresertib-npv-innovation-and-trend-analysis,10374,,1200
GDHCDR1200NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Repare Therapeutics Inc's Lunresertib</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Repare Therapeutics Inc's Lunresertib Drug Details:</strong></p>

<p> Lunresertib (RP-6306) is under development for the treatment of advanced solid tumors including metastatic colorectal cancer, ovarian, breast, hepatocellular, endometrial cancer, gastroesophageal cancer, fallopian tube cancer, peritoneal cancer, uterine cancer, triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma, non-small cell lung cancer, esophageal cancer, cholangiocarcinoma, breast cancer, head and neck cancer, soft tissue sarcoma, bladder cancer, cervical cancer, gastrointestinal stromal tumor (gist), melanoma, gallbladder cancer, vulvar cancer, sarcomas. It is administered through oral route. It acts by targeting Cyclin E 1 (CCNE1) and PKMYT1.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Repare Therapeutics Inc's Lunresertib Drug Details:</strong></p>

<p> Lunresertib (RP-6306) is under development for the treatment of advanced solid tumors including metastatic colorectal cancer, ovarian, breast, hepatocellular, endometrial cancer, gastroesophageal cancer, fallopian tube cancer, peritoneal cancer, uterine cancer, triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma, non-small cell lung cancer, esophageal cancer, cholangiocarcinoma, breast cancer, head and neck cancer, soft tissue sarcoma, bladder cancer, cervical cancer, gastrointestinal stromal tumor (gist), melanoma, gallbladder cancer, vulvar cancer, sarcomas. It is administered through oral route. It acts by targeting Cyclin E 1 (CCNE1) and PKMYT1.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Repare Therapeutics Inc",,,,,,,,,,,repare-therapeutics-incs-lunresertib-npv-innovation-and-trend-analysis,10374,,1200
GDHCDR1201NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's RG-6237</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's RG-6237 Drug Details:</strong></p>

<p> RG-6237 is under development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), neuromuscular disease and spinal muscular atrophy (SMA). The drug candidate is administered through subcutaneous route. It acts by targeting latent myostatin. The drug candidate is developed based on sweeping antibody technology. It is a new molecular entity (NME).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's RG-6237 Drug Details:</strong></p>

<p> RG-6237 is under development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), neuromuscular disease and spinal muscular atrophy (SMA). The drug candidate is administered through subcutaneous route. It acts by targeting latent myostatin. The drug candidate is developed based on sweeping antibody technology. It is a new molecular entity (NME).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-rg-6237-npv-innovation-and-trend-analysis,10374,,1201
GDHCDR1201NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's RG-6237</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's RG-6237 Drug Details:</strong></p>

<p> RG-6237 is under development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), neuromuscular disease and spinal muscular atrophy (SMA). The drug candidate is administered through subcutaneous route. It acts by targeting latent myostatin. The drug candidate is developed based on sweeping antibody technology. It is a new molecular entity (NME).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's RG-6237 Drug Details:</strong></p>

<p> RG-6237 is under development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), neuromuscular disease and spinal muscular atrophy (SMA). The drug candidate is administered through subcutaneous route. It acts by targeting latent myostatin. The drug candidate is developed based on sweeping antibody technology. It is a new molecular entity (NME).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-rg-6237-npv-innovation-and-trend-analysis,10374,,1201
GDHCDR1201NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: F. Hoffmann-La Roche Ltd's RG-6237</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's RG-6237 Drug Details:</strong></p>

<p> RG-6237 is under development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), neuromuscular disease and spinal muscular atrophy (SMA). The drug candidate is administered through subcutaneous route. It acts by targeting latent myostatin. The drug candidate is developed based on sweeping antibody technology. It is a new molecular entity (NME).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>F. Hoffmann-La Roche Ltd's RG-6237 Drug Details:</strong></p>

<p> RG-6237 is under development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), neuromuscular disease and spinal muscular atrophy (SMA). The drug candidate is administered through subcutaneous route. It acts by targeting latent myostatin. The drug candidate is developed based on sweeping antibody technology. It is a new molecular entity (NME).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"F. Hoffmann-La Roche Ltd",,,,,,,,,,,f-hoffmann-la-roche-ltds-rg-6237-npv-innovation-and-trend-analysis,10374,,1201
GDHCDR1202NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Shionogi & Co Ltd's S-309309</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Shionogi & Co Ltd's S-309309 Drug Details:</strong></p>

<p>S-309309 is under development for the treatment of obesity. It is administered through Oral route as capsule formulation. The drug candidate acts by targeting the monoacylglycerol acyltransferase-2 (MGAT2).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Shionogi & Co Ltd's S-309309 Drug Details:</strong></p>

<p>S-309309 is under development for the treatment of obesity. It is administered through Oral route as capsule formulation. The drug candidate acts by targeting the monoacylglycerol acyltransferase-2 (MGAT2).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Shionogi & Co Ltd",,,,,,,,,,,shionogi-and-co-ltds-s-309309-npv-innovation-and-trend-analysis,10374,,1202
GDHCDR1202NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Shionogi & Co Ltd's S-309309</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Shionogi & Co Ltd's S-309309 Drug Details:</strong></p>

<p>S-309309 is under development for the treatment of obesity. It is administered through Oral route as capsule formulation. The drug candidate acts by targeting the monoacylglycerol acyltransferase-2 (MGAT2).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Shionogi & Co Ltd's S-309309 Drug Details:</strong></p>

<p>S-309309 is under development for the treatment of obesity. It is administered through Oral route as capsule formulation. The drug candidate acts by targeting the monoacylglycerol acyltransferase-2 (MGAT2).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Shionogi & Co Ltd",,,,,,,,,,,shionogi-and-co-ltds-s-309309-npv-innovation-and-trend-analysis,10374,,1202
GDHCDR1202NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Shionogi & Co Ltd's S-309309</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Shionogi & Co Ltd's S-309309 Drug Details:</strong></p>

<p>S-309309 is under development for the treatment of obesity. It is administered through Oral route as capsule formulation. The drug candidate acts by targeting the monoacylglycerol acyltransferase-2 (MGAT2).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Shionogi & Co Ltd's S-309309 Drug Details:</strong></p>

<p>S-309309 is under development for the treatment of obesity. It is administered through Oral route as capsule formulation. The drug candidate acts by targeting the monoacylglycerol acyltransferase-2 (MGAT2).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Shionogi & Co Ltd",,,,,,,,,,,shionogi-and-co-ltds-s-309309-npv-innovation-and-trend-analysis,10374,,1202
GDHCDR1203NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Bolt Biotherapeutics Inc's Trastuzumab Imbotolimod</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Bolt Biotherapeutics Inc's Trastuzumab Imbotolimod Drug Details:</strong></p>

<p>Ttrastuzumab imbotolimod (BDC-1001) is under development for the treatment of HER2 low expressing and HER2 positive breast and non-breast HER2 advanced malignancies including gastric cancer, gastroesophageal,  colorectal cancer and endometrial cancer. It is administered through the intravenous route. BDC-1001 is an ISAC comprised of trastuzumab that acts by targeting HER2, conjugated to Bolt’s proprietary TLR7/8 agonist payload. These act by targeting toll-like receptor 7 (TLR7) and toll-like receptor 8 (TLR8). The drug candidate is developed based on the immune-stimulating antibody conjugate (ISAC) platform and Boltbody technology.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Bolt Biotherapeutics Inc's Trastuzumab Imbotolimod Drug Details:</strong></p>

<p>Ttrastuzumab imbotolimod (BDC-1001) is under development for the treatment of HER2 low expressing and HER2 positive breast and non-breast HER2 advanced malignancies including gastric cancer, gastroesophageal,  colorectal cancer and endometrial cancer. It is administered through the intravenous route. BDC-1001 is an ISAC comprised of trastuzumab that acts by targeting HER2, conjugated to Bolt’s proprietary TLR7/8 agonist payload. These act by targeting toll-like receptor 7 (TLR7) and toll-like receptor 8 (TLR8). The drug candidate is developed based on the immune-stimulating antibody conjugate (ISAC) platform and Boltbody technology.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Bolt Biotherapeutics Inc",,,,,,,,,,,bolt-biotherapeutics-incs-trastuzumab-imbotolimod-npv-innovation-and-trend-analysis,10374,,1203
GDHCDR1203NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Bolt Biotherapeutics Inc's Trastuzumab Imbotolimod</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Bolt Biotherapeutics Inc's Trastuzumab Imbotolimod Drug Details:</strong></p>

<p>Ttrastuzumab imbotolimod (BDC-1001) is under development for the treatment of HER2 low expressing and HER2 positive breast and non-breast HER2 advanced malignancies including gastric cancer, gastroesophageal,  colorectal cancer and endometrial cancer. It is administered through the intravenous route. BDC-1001 is an ISAC comprised of trastuzumab that acts by targeting HER2, conjugated to Bolt’s proprietary TLR7/8 agonist payload. These act by targeting toll-like receptor 7 (TLR7) and toll-like receptor 8 (TLR8). The drug candidate is developed based on the immune-stimulating antibody conjugate (ISAC) platform and Boltbody technology.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Bolt Biotherapeutics Inc's Trastuzumab Imbotolimod Drug Details:</strong></p>

<p>Ttrastuzumab imbotolimod (BDC-1001) is under development for the treatment of HER2 low expressing and HER2 positive breast and non-breast HER2 advanced malignancies including gastric cancer, gastroesophageal,  colorectal cancer and endometrial cancer. It is administered through the intravenous route. BDC-1001 is an ISAC comprised of trastuzumab that acts by targeting HER2, conjugated to Bolt’s proprietary TLR7/8 agonist payload. These act by targeting toll-like receptor 7 (TLR7) and toll-like receptor 8 (TLR8). The drug candidate is developed based on the immune-stimulating antibody conjugate (ISAC) platform and Boltbody technology.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Bolt Biotherapeutics Inc",,,,,,,,,,,bolt-biotherapeutics-incs-trastuzumab-imbotolimod-npv-innovation-and-trend-analysis,10374,,1203
GDHCDR1203NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Bolt Biotherapeutics Inc's Trastuzumab Imbotolimod</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Bolt Biotherapeutics Inc's Trastuzumab Imbotolimod Drug Details:</strong></p>

<p>Ttrastuzumab imbotolimod (BDC-1001) is under development for the treatment of HER2 low expressing and HER2 positive breast and non-breast HER2 advanced malignancies including gastric cancer, gastroesophageal,  colorectal cancer and endometrial cancer. It is administered through the intravenous route. BDC-1001 is an ISAC comprised of trastuzumab that acts by targeting HER2, conjugated to Bolt’s proprietary TLR7/8 agonist payload. These act by targeting toll-like receptor 7 (TLR7) and toll-like receptor 8 (TLR8). The drug candidate is developed based on the immune-stimulating antibody conjugate (ISAC) platform and Boltbody technology.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Bolt Biotherapeutics Inc's Trastuzumab Imbotolimod Drug Details:</strong></p>

<p>Ttrastuzumab imbotolimod (BDC-1001) is under development for the treatment of HER2 low expressing and HER2 positive breast and non-breast HER2 advanced malignancies including gastric cancer, gastroesophageal,  colorectal cancer and endometrial cancer. It is administered through the intravenous route. BDC-1001 is an ISAC comprised of trastuzumab that acts by targeting HER2, conjugated to Bolt’s proprietary TLR7/8 agonist payload. These act by targeting toll-like receptor 7 (TLR7) and toll-like receptor 8 (TLR8). The drug candidate is developed based on the immune-stimulating antibody conjugate (ISAC) platform and Boltbody technology.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Bolt Biotherapeutics Inc",,,,,,,,,,,bolt-biotherapeutics-incs-trastuzumab-imbotolimod-npv-innovation-and-trend-analysis,10374,,1203
GDHCDR1204NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Novo Nordisk AS's Lefelsiran Sodium</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's Lefelsiran Sodium Drug Details:</strong></p>

<p>Lefelsiran sodium (NN-6020) is under development for the treatment of alcohol use disorder. The drug candidates is a siRNA. The drug candidate is developed based on GalXC RNAi technology platform. It acts by targeting ALDH2. It is administered subcutaneously as a solution.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's Lefelsiran Sodium Drug Details:</strong></p>

<p>Lefelsiran sodium (NN-6020) is under development for the treatment of alcohol use disorder. The drug candidates is a siRNA. The drug candidate is developed based on GalXC RNAi technology platform. It acts by targeting ALDH2. It is administered subcutaneously as a solution.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Novo Nordisk AS",,,,,,,,,,,novo-nordisk-ass-lefelsiran-sodium-npv-innovation-and-trend-analysis,10374,,1204
GDHCDR1204NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Novo Nordisk AS's Lefelsiran Sodium</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's Lefelsiran Sodium Drug Details:</strong></p>

<p>Lefelsiran sodium (NN-6020) is under development for the treatment of alcohol use disorder. The drug candidates is a siRNA. The drug candidate is developed based on GalXC RNAi technology platform. It acts by targeting ALDH2. It is administered subcutaneously as a solution.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's Lefelsiran Sodium Drug Details:</strong></p>

<p>Lefelsiran sodium (NN-6020) is under development for the treatment of alcohol use disorder. The drug candidates is a siRNA. The drug candidate is developed based on GalXC RNAi technology platform. It acts by targeting ALDH2. It is administered subcutaneously as a solution.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Novo Nordisk AS",,,,,,,,,,,novo-nordisk-ass-lefelsiran-sodium-npv-innovation-and-trend-analysis,10374,,1204
GDHCDR1204NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Novo Nordisk AS's Lefelsiran Sodium</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's Lefelsiran Sodium Drug Details:</strong></p>

<p>Lefelsiran sodium (NN-6020) is under development for the treatment of alcohol use disorder. The drug candidates is a siRNA. The drug candidate is developed based on GalXC RNAi technology platform. It acts by targeting ALDH2. It is administered subcutaneously as a solution.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's Lefelsiran Sodium Drug Details:</strong></p>

<p>Lefelsiran sodium (NN-6020) is under development for the treatment of alcohol use disorder. The drug candidates is a siRNA. The drug candidate is developed based on GalXC RNAi technology platform. It acts by targeting ALDH2. It is administered subcutaneously as a solution.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Novo Nordisk AS",,,,,,,,,,,novo-nordisk-ass-lefelsiran-sodium-npv-innovation-and-trend-analysis,10374,,1204
GDHCDR1205NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Bristol-Myers Squibb Co's Lomedeucitinib</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Bristol-Myers Squibb Co's Lomedeucitinib Drug Details:</strong></p>

<p> Lomedeucitinib (BMS-986322) is under development for the treatment of plaque psoriasis. It is administered through oral route. The drug candidate act by targeting receptor tyrosine protein kinase (TYK2).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Bristol-Myers Squibb Co's Lomedeucitinib Drug Details:</strong></p>

<p> Lomedeucitinib (BMS-986322) is under development for the treatment of plaque psoriasis. It is administered through oral route. The drug candidate act by targeting receptor tyrosine protein kinase (TYK2).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Bristol-Myers Squibb Co",,,,,,,,,,,bristol-myers-squibb-cos-lomedeucitinib-npv-innovation-and-trend-analysis,10374,,1205
GDHCDR1205NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Bristol-Myers Squibb Co's Lomedeucitinib</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Bristol-Myers Squibb Co's Lomedeucitinib Drug Details:</strong></p>

<p> Lomedeucitinib (BMS-986322) is under development for the treatment of plaque psoriasis. It is administered through oral route. The drug candidate act by targeting receptor tyrosine protein kinase (TYK2).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Bristol-Myers Squibb Co's Lomedeucitinib Drug Details:</strong></p>

<p> Lomedeucitinib (BMS-986322) is under development for the treatment of plaque psoriasis. It is administered through oral route. The drug candidate act by targeting receptor tyrosine protein kinase (TYK2).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Bristol-Myers Squibb Co",,,,,,,,,,,bristol-myers-squibb-cos-lomedeucitinib-npv-innovation-and-trend-analysis,10374,,1205
GDHCDR1205NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Bristol-Myers Squibb Co's Lomedeucitinib</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Bristol-Myers Squibb Co's Lomedeucitinib Drug Details:</strong></p>

<p> Lomedeucitinib (BMS-986322) is under development for the treatment of plaque psoriasis. It is administered through oral route. The drug candidate act by targeting receptor tyrosine protein kinase (TYK2).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Bristol-Myers Squibb Co's Lomedeucitinib Drug Details:</strong></p>

<p> Lomedeucitinib (BMS-986322) is under development for the treatment of plaque psoriasis. It is administered through oral route. The drug candidate act by targeting receptor tyrosine protein kinase (TYK2).</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Bristol-Myers Squibb Co",,,,,,,,,,,bristol-myers-squibb-cos-lomedeucitinib-npv-innovation-and-trend-analysis,10374,,1205
GDHCDR1206NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Takeda Pharmaceutical Co Ltd's TAK-881</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's TAK-881 Drug Details:</strong></p>

<p>TAK-881 is under development for the treatment of primary immunodeficiency. It is a next generation drug candidate comprises of human normal immunoglobulin IgG combined with recombinant human hyaluronidase. The drug candidate is administered through subcutaneous route and is being developed based on plasma derived therapy platform.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's TAK-881 Drug Details:</strong></p>

<p>TAK-881 is under development for the treatment of primary immunodeficiency. It is a next generation drug candidate comprises of human normal immunoglobulin IgG combined with recombinant human hyaluronidase. The drug candidate is administered through subcutaneous route and is being developed based on plasma derived therapy platform.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Takeda Pharmaceutical Co Ltd",,,,,,,,,,,takeda-pharmaceutical-co-ltds-tak-881-npv-innovation-and-trend-analysis,10374,,1206
GDHCDR1206NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Takeda Pharmaceutical Co Ltd's TAK-881</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's TAK-881 Drug Details:</strong></p>

<p>TAK-881 is under development for the treatment of primary immunodeficiency. It is a next generation drug candidate comprises of human normal immunoglobulin IgG combined with recombinant human hyaluronidase. The drug candidate is administered through subcutaneous route and is being developed based on plasma derived therapy platform.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's TAK-881 Drug Details:</strong></p>

<p>TAK-881 is under development for the treatment of primary immunodeficiency. It is a next generation drug candidate comprises of human normal immunoglobulin IgG combined with recombinant human hyaluronidase. The drug candidate is administered through subcutaneous route and is being developed based on plasma derived therapy platform.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Takeda Pharmaceutical Co Ltd",,,,,,,,,,,takeda-pharmaceutical-co-ltds-tak-881-npv-innovation-and-trend-analysis,10374,,1206
GDHCDR1206NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Takeda Pharmaceutical Co Ltd's TAK-881</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's TAK-881 Drug Details:</strong></p>

<p>TAK-881 is under development for the treatment of primary immunodeficiency. It is a next generation drug candidate comprises of human normal immunoglobulin IgG combined with recombinant human hyaluronidase. The drug candidate is administered through subcutaneous route and is being developed based on plasma derived therapy platform.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Takeda Pharmaceutical Co Ltd's TAK-881 Drug Details:</strong></p>

<p>TAK-881 is under development for the treatment of primary immunodeficiency. It is a next generation drug candidate comprises of human normal immunoglobulin IgG combined with recombinant human hyaluronidase. The drug candidate is administered through subcutaneous route and is being developed based on plasma derived therapy platform.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Takeda Pharmaceutical Co Ltd",,,,,,,,,,,takeda-pharmaceutical-co-ltds-tak-881-npv-innovation-and-trend-analysis,10374,,1206
GDHCDR1207NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: DICE Therapeutics Inc's DC-806</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,1970/01/01,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>DICE Therapeutics Inc's DC-806 Drug Details:</strong></p>

<p>S-011806 is under development for the treatment of plaque psoriasis and other IL-17 mediated chronic immunology disorders. It is administered by the oral route. It acts by targeting IL-17.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>DICE Therapeutics Inc's DC-806 Drug Details:</strong></p>

<p>S-011806 is under development for the treatment of plaque psoriasis and other IL-17 mediated chronic immunology disorders. It is administered by the oral route. It acts by targeting IL-17.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"DICE Therapeutics Inc",,,,,,,,,,,dice-therapeutics-incs-dc-806-npv-innovation-and-trend-analysis,10374,,1207
GDHCDR1207NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: DICE Therapeutics Inc's DC-806</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,1970/01/01,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>DICE Therapeutics Inc's DC-806 Drug Details:</strong></p>

<p>S-011806 is under development for the treatment of plaque psoriasis and other IL-17 mediated chronic immunology disorders. It is administered by the oral route. It acts by targeting IL-17.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>DICE Therapeutics Inc's DC-806 Drug Details:</strong></p>

<p>S-011806 is under development for the treatment of plaque psoriasis and other IL-17 mediated chronic immunology disorders. It is administered by the oral route. It acts by targeting IL-17.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"DICE Therapeutics Inc",,,,,,,,,,,dice-therapeutics-incs-dc-806-npv-innovation-and-trend-analysis,10374,,1207
GDHCDR1207NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: DICE Therapeutics Inc's DC-806</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,1970/01/01,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>DICE Therapeutics Inc's DC-806 Drug Details:</strong></p>

<p>S-011806 is under development for the treatment of plaque psoriasis and other IL-17 mediated chronic immunology disorders. It is administered by the oral route. It acts by targeting IL-17.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>DICE Therapeutics Inc's DC-806 Drug Details:</strong></p>

<p>S-011806 is under development for the treatment of plaque psoriasis and other IL-17 mediated chronic immunology disorders. It is administered by the oral route. It acts by targeting IL-17.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"DICE Therapeutics Inc",,,,,,,,,,,dice-therapeutics-incs-dc-806-npv-innovation-and-trend-analysis,10374,,1207
GDHCDR1208NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Rani Therapeutics LLC's Octreotide</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Rani Therapeutics LLC's Octreotide Drug Details:</strong></p>

<p>Octreotide (RT-101) is under development for the treatment of acromegaly and neuroendocrine tumors. It is administered through oral route as capsule. It acts by targeting somatostatin receptor subtype 2 and subtype 5 (SSTR2 and SSTR5) and is being developed based on RaniPill technology platform.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Rani Therapeutics LLC's Octreotide Drug Details:</strong></p>

<p>Octreotide (RT-101) is under development for the treatment of acromegaly and neuroendocrine tumors. It is administered through oral route as capsule. It acts by targeting somatostatin receptor subtype 2 and subtype 5 (SSTR2 and SSTR5) and is being developed based on RaniPill technology platform.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Rani Therapeutics LLC",,,,,,,,,,,rani-therapeutics-llcs-octreotide-npv-innovation-and-trend-analysis,10374,,1208
GDHCDR1208NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Rani Therapeutics LLC's Octreotide</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Rani Therapeutics LLC's Octreotide Drug Details:</strong></p>

<p>Octreotide (RT-101) is under development for the treatment of acromegaly and neuroendocrine tumors. It is administered through oral route as capsule. It acts by targeting somatostatin receptor subtype 2 and subtype 5 (SSTR2 and SSTR5) and is being developed based on RaniPill technology platform.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Rani Therapeutics LLC's Octreotide Drug Details:</strong></p>

<p>Octreotide (RT-101) is under development for the treatment of acromegaly and neuroendocrine tumors. It is administered through oral route as capsule. It acts by targeting somatostatin receptor subtype 2 and subtype 5 (SSTR2 and SSTR5) and is being developed based on RaniPill technology platform.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Rani Therapeutics LLC",,,,,,,,,,,rani-therapeutics-llcs-octreotide-npv-innovation-and-trend-analysis,10374,,1208
GDHCDR1208NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Rani Therapeutics LLC's Octreotide</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Rani Therapeutics LLC's Octreotide Drug Details:</strong></p>

<p>Octreotide (RT-101) is under development for the treatment of acromegaly and neuroendocrine tumors. It is administered through oral route as capsule. It acts by targeting somatostatin receptor subtype 2 and subtype 5 (SSTR2 and SSTR5) and is being developed based on RaniPill technology platform.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Rani Therapeutics LLC's Octreotide Drug Details:</strong></p>

<p>Octreotide (RT-101) is under development for the treatment of acromegaly and neuroendocrine tumors. It is administered through oral route as capsule. It acts by targeting somatostatin receptor subtype 2 and subtype 5 (SSTR2 and SSTR5) and is being developed based on RaniPill technology platform.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Rani Therapeutics LLC",,,,,,,,,,,rani-therapeutics-llcs-octreotide-npv-innovation-and-trend-analysis,10374,,1208
GDHCDR1209NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Novo Nordisk AS's NN-9932</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's NN-9932 Drug Details:</strong></p>

<p>Semaglutide (NN9932) is under development for the treatment of obesity. It is administered by oral route in the form of tablet. The therapeutic candidate acts as glucagon like peptide 1 receptor (GLP1R) agonist.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's NN-9932 Drug Details:</strong></p>

<p>Semaglutide (NN9932) is under development for the treatment of obesity. It is administered by oral route in the form of tablet. The therapeutic candidate acts as glucagon like peptide 1 receptor (GLP1R) agonist.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Novo Nordisk AS",,,,,,,,,,,novo-nordisk-ass-nn-9932-npv-innovation-and-trend-analysis,10374,,1209
GDHCDR1209NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Novo Nordisk AS's NN-9932</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's NN-9932 Drug Details:</strong></p>

<p>Semaglutide (NN9932) is under development for the treatment of obesity. It is administered by oral route in the form of tablet. The therapeutic candidate acts as glucagon like peptide 1 receptor (GLP1R) agonist.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's NN-9932 Drug Details:</strong></p>

<p>Semaglutide (NN9932) is under development for the treatment of obesity. It is administered by oral route in the form of tablet. The therapeutic candidate acts as glucagon like peptide 1 receptor (GLP1R) agonist.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Novo Nordisk AS",,,,,,,,,,,novo-nordisk-ass-nn-9932-npv-innovation-and-trend-analysis,10374,,1209
GDHCDR1209NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Novo Nordisk AS's NN-9932</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's NN-9932 Drug Details:</strong></p>

<p>Semaglutide (NN9932) is under development for the treatment of obesity. It is administered by oral route in the form of tablet. The therapeutic candidate acts as glucagon like peptide 1 receptor (GLP1R) agonist.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Novo Nordisk AS's NN-9932 Drug Details:</strong></p>

<p>Semaglutide (NN9932) is under development for the treatment of obesity. It is administered by oral route in the form of tablet. The therapeutic candidate acts as glucagon like peptide 1 receptor (GLP1R) agonist.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Novo Nordisk AS",,,,,,,,,,,novo-nordisk-ass-nn-9932-npv-innovation-and-trend-analysis,10374,,1209
GDHCDR1210NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Shenzhen Salubris Pharmaceuticals Co Ltd's Teriparatide LA</strong></p>","Single User",500,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Shenzhen Salubris Pharmaceuticals Co Ltd's Teriparatide LA Drug Details:</strong></p>

<p>SAL-056 (long-acting teriparatide) is under development for the treatment of osteoporosis in postmenopausal women. The drug candidate acts by targeting parathyroid hormone receptor. It is administered through subcutaneous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Shenzhen Salubris Pharmaceuticals Co Ltd's Teriparatide LA Drug Details:</strong></p>

<p>SAL-056 (long-acting teriparatide) is under development for the treatment of osteoporosis in postmenopausal women. The drug candidate acts by targeting parathyroid hormone receptor. It is administered through subcutaneous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Shenzhen Salubris Pharmaceuticals Co Ltd",,,,,,,,,,,shenzhen-salubris-pharmaceuticals-co-ltds-teriparatide-la-npv-innovation-and-trend-analysis,10374,,1210
GDHCDR1210NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Shenzhen Salubris Pharmaceuticals Co Ltd's Teriparatide LA</strong></p>","Site User",750,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Shenzhen Salubris Pharmaceuticals Co Ltd's Teriparatide LA Drug Details:</strong></p>

<p>SAL-056 (long-acting teriparatide) is under development for the treatment of osteoporosis in postmenopausal women. The drug candidate acts by targeting parathyroid hormone receptor. It is administered through subcutaneous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Shenzhen Salubris Pharmaceuticals Co Ltd's Teriparatide LA Drug Details:</strong></p>

<p>SAL-056 (long-acting teriparatide) is under development for the treatment of osteoporosis in postmenopausal women. The drug candidate acts by targeting parathyroid hormone receptor. It is administered through subcutaneous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Shenzhen Salubris Pharmaceuticals Co Ltd",,,,,,,,,,,shenzhen-salubris-pharmaceuticals-co-ltds-teriparatide-la-npv-innovation-and-trend-analysis,10374,,1210
GDHCDR1210NPV-MP,1,1,1,,,,"Product Insights","<p><strong>Net Present Value Model: Shenzhen Salubris Pharmaceuticals Co Ltd's Teriparatide LA</strong></p>","Enterprise Site User",1000,Pharmaceuticals,,,Global,7,2023/09/15,"<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Shenzhen Salubris Pharmaceuticals Co Ltd's Teriparatide LA Drug Details:</strong></p>

<p>SAL-056 (long-acting teriparatide) is under development for the treatment of osteoporosis in postmenopausal women. The drug candidate acts by targeting parathyroid hormone receptor. It is administered through subcutaneous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>","<p>Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.</p>

<p><img loading=""lazy"" class=""size-full wp-image-3244937 aligncenter"" src=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png"" alt="" width="" 863""="""" height=""601"" srcset=""https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 863w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 250w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 700w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 768w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 120w, https://www.globaldata.com/wp-content/uploads/2022/11/NPV-New.png 600w"" sizes=""(max-width: 863px) 100vw, 863px""></p>

<p><strong>Shenzhen Salubris Pharmaceuticals Co Ltd's Teriparatide LA Drug Details:</strong></p>

<p>SAL-056 (long-acting teriparatide) is under development for the treatment of osteoporosis in postmenopausal women. The drug candidate acts by targeting parathyroid hormone receptor. It is administered through subcutaneous route.</p>

<p><strong>Report Coverage</strong></p>

<p>GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.</p>",,"<ul><li>Better understand the quantitative value of a specific drug</li>
<li>Obtain another data source to use in the valuation of the company/drug</li>
<li>Create or support internal NPV models to improve accuracy</li>
<li>Understand a drug's expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.</li></ul>",,,"Shenzhen Salubris Pharmaceuticals Co Ltd",,,,,,,,,,,shenzhen-salubris-pharmaceuticals-co-ltds-teriparatide-la-npv-innovation-and-trend-analysis,10374,,1210
